Pharmacokinetic — Pharmacodynamic Relationships

  • Pierre Canal
  • Etienne Chatelut


Research of relationships between pharmacokinetics and pharmacodynamics in clinical oncology should result in a better use of anticancer drugs. The goal of these approaches is to improve cancer chemotherapy by optimising drug therapy in individual patients. After some recalls about general principles of pharmacokinetics and pharmacodynamics, the different models used for analysing pharmacokinetics-pharmacodynamics relationships will be defined. Before considering the different methods of adaptive dosing of anticancer drugs, the different reasons of variability in pharmacokinetics will be described briefly.


Anticancer Drug Therapeutic Drug Monitoring Plasma Protein Binding Platinum Compound Platelet Nadir 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ackland S.P., Ratain M.J., Vogelzang N.J., et al., 1989, Pharmacokinetics and pharmacodynamics of long-term continuous infusion doxorubicin. Clin. Pharmacol. Ther. 45, 340–347.CrossRefPubMedGoogle Scholar
  2. Ayash L.J., Wright J.E., Tretyakov O. et al.,1992, Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumour response. J. Clin. Oncol. 10, 995–1000.PubMedGoogle Scholar
  3. Beal S.L., and Sheiner L.B, 1985.: Methodology of population pharmacokinetics, in: Drug fate and metabolism Garrett E.R., Hirtz J. (eds) New York, NY, Marcel Decker, (Vol. 5)., pp 135–183.Google Scholar
  4. Beal S.L., Boeckmann A.J., and Sheiner L.B, 1992., NONMEM users guides, Part VI: PREDPP guide. Technical Report of the Division of Clinical Pharmacology, University of California, San Francisco.Google Scholar
  5. Bennett C.L., Sinkule J.A., Schilsky R.L. et al., 1987, Phase I clinical and pharmacological study of 72-hour continuous infusion etoposide in patients with advanced cancer. Cancer Res., 47,1952–1957.PubMedGoogle Scholar
  6. Calvert A.H., Newell D.R., Gumbrell L.A., et al. 1989, Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7:1748–1756.PubMedGoogle Scholar
  7. Calvert A.H., Judson I., Van der Vijgh W.J.F., 1993, Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. Cancer Surveys 17, 189–217.PubMedGoogle Scholar
  8. Calvert A.H., 1994, Dose optimisation of carboplatin in adults. Anticancer Res. 14, 2273–2278.PubMedGoogle Scholar
  9. Chatelut E., Canal P., Brunner V., et al., 1995, Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J. Natl. Cancer Inst. 87, 573–580.CrossRefPubMedGoogle Scholar
  10. Cockroft D.W., and Gault M.H.,1976, Prediction of creatinine clearance from serum creatinine. Nephron 16, 31–41.CrossRefGoogle Scholar
  11. Desai Z.R., van der Berg H.W., Bridges J.M., Shanks R.G., 1982, Can severe vincristine neurotoxicity be prevented? Cancer Chemother. Pharmacol. 8, 211–214.Google Scholar
  12. Desoize B., Dumont P., Manot L., et al., 1994, Comparison of two dose prediction models for cisplatin. Anticancer Res. 14, 2285–2290.PubMedGoogle Scholar
  13. Desoize B., Maréchal F., Cattan A., 1990, Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours. Br. J. Cancer 62, 840–841.CrossRefPubMedGoogle Scholar
  14. Egorin M.J., Therapeutic drug monitoring and dose optimisation in oncology. In Workman P (ed): New Approaches in Cancer Pharmacology: Drug Design and Development. Berlin: Springler-Verlag, 1992, pp 75–91.CrossRefGoogle Scholar
  15. Egorin M.J., Reyno L.M., Canetta R.M., et al., 1994, Modeling toxicity and response in carboplatin-based combination chemotherapy. Semin. Oncol. 21, 7–19.PubMedGoogle Scholar
  16. Egorin M.J., Van Echo D.A, Olman E.A., et al., 1985, Prospective validation of a pharmacologically based dosing scheme for cis-diamminedichloroplatinum (II) analogue diamminecyclobutane dicarboxylatoplatinum. Cancer Res. 45, 6502–6506.PubMedGoogle Scholar
  17. Egorin M.J., Van Echo D.A, Tipping SJ, et al., 1984, Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutane dicarboxylato) platinum in patients with impaired renal function. Cancer Res 44, 5432–5438.PubMedGoogle Scholar
  18. Etienne M.C., Lagrange J.L; Dassonville O., Fleming R., Thyss A., Renée N., Schneider M., Demard F., Milano G.,1994, Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol. 12, 2248–2253.PubMedGoogle Scholar
  19. Evans W.E., Crom W.E., Abromowitch M. et al., 1989, Clinical phannacodynamics of high-dose methotrexate in acute lymphoblastic leukemia. N. Engl. J. Med. 314, 471–477.CrossRefGoogle Scholar
  20. Fichtinger-Schepman AMJ, van der Velde-Visser SD., Van Dijk-Knijnenburg HCM, Van Oosterom AT., Baan RA., Berends F., 1990, Kinetics of formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res. 50, 7887–7894.PubMedGoogle Scholar
  21. Fichtinger-Schepman A.M.J., van Oosterom A.T., Lohman P.H.M., Berends F., 1987, Cis-diamminedichloroplatinum (II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct formation and removal after a single dose of cis-diamminedichloroplatinum (II). Cancer Res. 47, 3000–3004.PubMedGoogle Scholar
  22. Forastiere A.A., Belliveau J.F., Goren M.P., 1988, Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent cis-diamminedichloroplatinum (II) in head and neck cancer patients. Cancer Res. 48, 3869–3874.PubMedGoogle Scholar
  23. Gregg R.W., Molepo J.M., Monpetit V.J.A., et al., 1992, Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues and morphologic evidence of toxicity. J. Clin. Oncol. 10, 795–803.PubMedGoogle Scholar
  24. Grochow L.B., Jones R.J., Brundrett R.B., et al., 1990, Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation, Cancer Chemother. Pharmacol. 25, 55–61.Google Scholar
  25. Horwich A., Dearnaley D.F., Nicholls J. et al., 1991, Effectiveness of carboplatin, etoposide and bleomycin combination chemotherapy in good prognosis metastatic testicular non seminomatous germ cell tumours. J. Clin. Oncol. 9, 62–69.PubMedGoogle Scholar
  26. Jodrell DI, Egorin MJ, Canetta RM et al., 1992, Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J. Clin. Oncol. 10, 520–528.PubMedGoogle Scholar
  27. Kantarjian G., Estey EH., Plunkett W. et al., 1986, Phase I-II clinical and pharmacological studies of high-dose cytosine arabinoside in refractory leukemia. Am. J. Med. 81, 387–394.CrossRefPubMedGoogle Scholar
  28. Lennard I., Lilleyman JS., 1987, Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J. Clin. Oncol. 7, 1816–1823.Google Scholar
  29. Lennard L. van Loon JA., Lilleyman JS, Weinshilboum RM., 1987, Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin. Pharmacol. Ther. 41, 18–25.CrossRefPubMedGoogle Scholar
  30. Ma J., Verweij J., Planting AST., de Boer-Dennert M., van der Burg MEL., Stoter G., Schellens JHM., 1994, Pharmacokinetic-dynamic relationship of weekly high dose cisplatin in solid tumor patients. Proc. Am. Assoc; Clin. Oncol. 13, 133.Google Scholar
  31. Marina N.M., Rodman J., Murry D.J., et al., 1994, Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. J. Natl. Cancer Inst. 86, 544–548.CrossRefPubMedGoogle Scholar
  32. Marina N.M., Rodman J., Shema S.J., et al., 1993, Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J. Clin. Oncol. 11, 554–560.PubMedGoogle Scholar
  33. Milano G., Etienne M.C., Renée N. et al., 1994, Relationship between fluorouracil systemic exposure and tumor response and patient survival, J. Clin. Oncol. 12: 1291–1297.PubMedGoogle Scholar
  34. Miller AA., Stewart CF., Tolley EA., 1990, Clinical pharmacodynamics of continuous infusion etoposide; Cancer Chemother. Pharmacol. 25, 361–366.Google Scholar
  35. Moore MJ., Erlichman C., 1987, Therapeutic drug monitoring in oncology, Problems and potential in antineoplastic therapy. Clin. Pharmacokin. 13, 205–227.CrossRefGoogle Scholar
  36. Motzer RJ., Reed E., Perera F., Tang D., Shamkhani H., Poirier MC., Tsai WY., Parker R., Bosl GJ., 1994, Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer 73, 2843–2852.CrossRefPubMedGoogle Scholar
  37. Newell DR., 1994, Can pharmacokinetic and pharmacodynamic studies improve cancer chemotherapy? Ann. Oncol. 5, S9–S15.CrossRefGoogle Scholar
  38. Newell DR., Pearson ADJ., Bolmanno K., et al., 1993, Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. J. Clin. Oncol. 11, 2314–2323.PubMedGoogle Scholar
  39. Paredes J., Hong W.K., Felder T.B. et al., 1988, Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck, J. Clin. Oncol. 6: 955–962.PubMedGoogle Scholar
  40. Parker R.J., Gill I., Tarone R., Vionnet JA., Grunberg S., Muggia FM., Reed E., 1991, Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorbance spectrometry. Carcinogenesis, 12, 1253–1258.CrossRefPubMedGoogle Scholar
  41. Ratain M.J, Schlisky RL, Conley B.A, Egorin M.J., 1990, Pharmacodynamics in cancer therapy. J. Clin. Oncol. 8, 1739–1753.PubMedGoogle Scholar
  42. Ratain M.J., Mick R., Berezin F. et al., 1991a, Paradoxical relationship between acetylor phenotype and amonafide toxicity. Clin. Pharmacol. Ther. 50, 573–579.CrossRefPubMedGoogle Scholar
  43. Ratain M.J., Mick R., Schilsky RI., et al., 1991b., Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J. Clin. Oncol. 9, 1490–1486.Google Scholar
  44. Reece PA., Stafford L, Russel J., Khan M., Gill P.G., 1987, Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak untrafilterable platinum levels and nephrotoxicity. J. Clin. Oncol. 5, 304–309.PubMedGoogle Scholar
  45. Reed E., Ostchega Y., Steinberg S.M., Yuspa. H., Young R.C., Ozols RF., Poirier M.C., 1990, Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res. 50, 2256–2260.PubMedGoogle Scholar
  46. Reed E., Ozols R.F., Tarone R., Yuspa S.H., Poirier M.C., 1987, Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc. Natl. Acad. Sci. USA, 84, 5024–5028.CrossRefPubMedGoogle Scholar
  47. Reed E., Ozols R.F., Tarone R., Yuspa S.H., Poirier M.C., 1988, The measurement of cisplatin-DNA adduct in testicular cancer patients. Carcinogenesis 9, 1909–1911.CrossRefPubMedGoogle Scholar
  48. Reed E., Parker R.J., Gill L, Bicher A., Dabholkar M., Vionnet J.A., Bostick-Burton F., Tarone R., Muggia F.M., 1993, Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res. 53, 3694–3699.PubMedGoogle Scholar
  49. Rodman J.H., Abromowitch M. Sinkule J.A., Hayes F.A., Rivera G.K., Evans W.E., 1987, Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a Phase I trial. J. Clin. Oncol. 5, 1007–1014.PubMedGoogle Scholar
  50. Rodman J.H., Maneuval D.C., Magill J.H. et al., 1993, Measurement of Tc-99m DTPA serum clearance for the estimation of glomerular filtration rate in children with cancer. Pharmacotherapy 13, 10–16.PubMedGoogle Scholar
  51. Rowinsky E.K., Gilbert M., McGuire W.P., et al., 1991, Sequences of taxol and cisplatin: a phase I and pharmacologie study. J. Clin. Oncol. 9, 1692–1703.PubMedGoogle Scholar
  52. Santini J., Milano G., Thyss A. et al., 1989, FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index for head and neck cancer. Br. J. Cancer. 59, 287–290.CrossRefPubMedGoogle Scholar
  53. Sorensen B.T., Strômgren A., Jakobsen P., et al., 1991, Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients. Cancer Chemother. Pharmacol. 28, 337–341.CrossRefGoogle Scholar
  54. Stewart C.F., Arbuck S.G., Fleming R.A., Evans W.E., 1991, Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin. Pharmacol. Ther. 50, 385–393.CrossRefPubMedGoogle Scholar
  55. Thomas D.J., Clifford S.C., Aherne W., et al., 1994, Pharmacokinetic determinants of antitumour activity in bladder cancer patients. Br. J. Cancer 69, supll XXI, 30.Google Scholar
  56. Van der Vijgh W.J.F., 1991, Clinical pharmacokinetics of carboplatin. Clin. Pharmacokinet. 21, 242–261.CrossRefPubMedGoogle Scholar
  57. Van Warmerdam L.J.C., Verweij J., Schellens J.H.M., et al., 1995, Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother. Pharmacol. 35, 237–245.CrossRefPubMedGoogle Scholar
  58. Vermorken J.B., Van der Vijgh W.J.F., Klein I., et al., 1984, Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat. Rep. 68, 505–513.PubMedGoogle Scholar
  59. Whitehead V.M., Rosenblatt D.S., Vichich M.J., et al., 1990, Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood, 76, 44–49.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Pierre Canal
    • 1
  • Etienne Chatelut
    • 1
  1. 1.Pharmacology LaboratoryCentre Claudius RegaudToulouse CedexFrance

Personalised recommendations